Monoclonal antibody reduced lower respiratory tract infections due to RSV in healthy infants
News
J&J COVID-19 vaccine hold lifted in the US
Advisory committee voted to resume use of the vaccine under its emergency use authorisation
BMS’ deucravacitinib tops Otezla in two psoriasis studies
Deucravacitinib demonstrated superior skin clearance compared with Otezla
Roche’s Enspryng leads latest CHMP recommendations
CHMP adopted positive opinions for eight new medicines in its April meeting
PARP inhibitors could exploit weaknesses in a range of cancers
Drug type could offer a new approach to treating a number of cancers with PBRM1 mutations
FDA approves GSK’s Jemperli for dMMR endometrial cancer
PD-1 inhibitor approved to treat patients with specific biomarker
BMS to invest in new cell therapy manufacturing site in Europe
Construction on Leiden, Netherlands site anticipated to begin later this year
MHRA authorises Amarin’s heart drug Vazkepa
Drug demonstrated a 25% relative risk reduction in the first occurrence of major adverse cardiovascular events in REDUCE-IT trial
Less than 1 month until CROY 2021 closes for entry
The 2021 Clinical Researcher of the Year – The Americas will be closing for entry on the 14th of May.
Lilly, Incyte report positive results for baricitinib in alopecia areata
Oral JAK inhibitor improved hair regrowth across both dosing groups
New report suggests the gender pay gap for doctors increased during pandemic
Medscape survey finds female doctors reported 30% lower pay compared to male doctors
Novo Nordisk plans study of oral semaglutide in obesity
Study will include approximately 1,000 people with obesity or overweight with comorbidities
NHS leaders warn of a ‘chronic undersupply’ of staff
Six organisations representing most of the NHS workforce pen joint letter calling for action
GW Pharma’s Epidyolex scores new EU indication
Cannabis-based medicine approved for the treatment of seizures associated with tuberous sclerosis complex
J&J resumes roll-out of COVID-19 vaccine in EU
EMA’s safety committee has confirmed the overall benefit-risk profile of the jab
